Print Issue: July 01, 2010

Imaging Agent for Bladder Cancer Okayed

The FDA has approved Cysview (hexaminolevulinate HCl), an optical imaging agent indicated for use in the cystoscopic detection of non-muscle-invasive papillary bladder cancer in patients suspected or known to have lesions on the basis of prior cystoscopy.

Next post in Hyperphosphatemia